These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35461831)

  • 21. SCORE2 Report 20: Relationship of Treatment Discontinuation With Visual Acuity and Central Subfield Thickness Outcomes.
    Scott IU; Oden NL; VanVeldhuisen PC; Ip MS; Blodi BA;
    Am J Ophthalmol; 2023 Apr; 248():157-163. PubMed ID: 36584835
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
    Ding X; Li J; Hu X; Yu S; Pan J; Tang S
    Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SCORE2 Report 5: Vision-Related Function in Patients With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion.
    Scott IU; Figueroa MJ; Oden NL; Ip MS; Blodi BA; VanVeldhuisen PC;
    Am J Ophthalmol; 2017 Dec; 184():147-156. PubMed ID: 29074161
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aflibercept for Previously Treated Macular Edema Associated with Central Retinal Vein Occlusions: 1-Year Results of the NEWTON Study.
    Khurana RN; Chang LK; Bansal AS; Palmer JD; Wu C; Wieland MR
    Ophthalmol Retina; 2018 Feb; 2(2):128-133. PubMed ID: 31047339
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT.
    Hykin P; Prevost AT; Sivaprasad S; Vasconcelos JC; Murphy C; Kelly J; Ramu J; Alshreef A; Flight L; Pennington R; Hounsome B; Lever E; Metry A; Poku E; Yang Y; Harding SP; Lotery A; Chakravarthy U; Brazier J
    Health Technol Assess; 2021 Jun; 25(38):1-196. PubMed ID: 34132192
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcome of "treat and monitor" regimen of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion.
    Pichi F; Elbarky AM; Elhamaky TR
    Int Ophthalmol; 2019 Jan; 39(1):145-153. PubMed ID: 29274022
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion: 18-month results in real-life data.
    Chatziralli I; Theodossiadis G; Moschos MM; Mitropoulos P; Theodossiadis P
    Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1093-1100. PubMed ID: 28214955
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-Utility Comparison of Bevacizumab and Aflibercept in the Treatment of Central or Hemiretinal Vein Occlusion in the SCORE2 Trial.
    Kymes SM; Oden NL; VanVeldhuisen PC; Scott IU; Ip MS; Blodi BA; King J;
    JAMA Ophthalmol; 2023 Jun; 141(6):554-561. PubMed ID: 37166820
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusion.
    Saishin Y; Ito Y; Fujikawa M; Sawada T; Ohji M
    Jpn J Ophthalmol; 2017 Jan; 61(1):67-73. PubMed ID: 27660163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of Switching to Aflibercept in Treatment Resistant Macular Edema Secondary to Retinal Vein Occlusion.
    Spooner K; Fraser-Bell S; Hong T; Chang A
    Asia Pac J Ophthalmol (Phila); 2020; 9(1):48-53. PubMed ID: 31990746
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association between early and late response in eyes with central or hemiretinal vein occlusion treated with anti-VEGF agents : SCORE2 report 12: secondary analysis of the SCORE2 clinical trial.
    Khurana RN; Oden NL; VanVeldhuisen PC; Scott IU; Blodi BA; Ip MS;
    Graefes Arch Clin Exp Ophthalmol; 2021 Jul; 259(7):1839-1851. PubMed ID: 33415354
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion.
    Pfau M; Fassnacht-Riederle H; Becker MD; Graf N; Michels S
    Ophthalmic Res; 2015; 54(3):150-6. PubMed ID: 26413794
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison between Ozurdex and intravitreal anti-vascular endothelial growth factor treatment for retinal vein occlusion-related macular edema: A systematic review and meta-analysis of randomized controlled trials.
    Hu Q; Li H; Xu W; Du Y; Ma C; He J
    Indian J Ophthalmol; 2019 Nov; 67(11):1800-1809. PubMed ID: 31638037
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Simultaneous intravitreal dexamethasone and aflibercept for refractory macular edema secondary to retinal vein occlusion.
    Giuffrè C; Cicinelli MV; Marchese A; Coppola M; Parodi MB; Bandello F
    Graefes Arch Clin Exp Ophthalmol; 2020 Apr; 258(4):787-793. PubMed ID: 31897703
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Spectral Domain OCT Predictors of Visual Acuity in the Study of COmparative Treatments for REtinal Vein Occlusion 2: SCORE 2 Report 15.
    Etheridge T; Blodi B; Oden N; Van Veldhuisen P; Scott IU; Ip MS; Mititelu M; Domalpally A
    Ophthalmol Retina; 2021 Oct; 5(10):991-998. PubMed ID: 33373715
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Response to aflibercept as secondary therapy in patients with persistent retinal edema due to central retinal vein occlusion initially treated with bevacizumab or ranibizumab.
    Eadie JA; Ip MS; Kulkarni AD
    Retina; 2014 Dec; 34(12):2439-43. PubMed ID: 24999721
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-Term Follow-Up Changes of Central Choroidal Thickness Thinning after Repeated Anti-VEGF Therapy Injections in Patients with Central Retinal Vein Occlusion-Related Macular Edema with Systemic Hypertension.
    Kida T; Osuka S; Fukumoto M; Sato T; Harino S; Oku H; Ikeda T
    Ophthalmologica; 2020; 243(2):102-109. PubMed ID: 31851998
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema.
    Wells JA; Glassman AR; Jampol LM; Aiello LP; Antoszyk AN; Baker CW; Bressler NM; Browning DJ; Connor CG; Elman MJ; Ferris FL; Friedman SM; Melia M; Pieramici DJ; Sun JK; Beck RW;
    JAMA Ophthalmol; 2016 Feb; 134(2):127-34. PubMed ID: 26605836
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Longitudinal Panretinal Leakage and Ischemic Indices in Retinal Vascular Disease after Aflibercept Therapy: The PERMEATE Study.
    Figueiredo N; Srivastava SK; Singh RP; Babiuch A; Sharma S; Rachitskaya A; Talcott K; Reese J; Hu M; Ehlers JP
    Ophthalmol Retina; 2020 Feb; 4(2):154-163. PubMed ID: 31757691
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study.
    Clark WL; Boyer DS; Heier JS; Brown DM; Haller JA; Vitti R; Kazmi H; Berliner AJ; Erickson K; Chu KW; Soo Y; Cheng Y; Campochiaro PA
    Ophthalmology; 2016 Feb; 123(2):330-336. PubMed ID: 26522708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.